Sitemap
December 09, 2012 Articles
Filter by Available Specialty
- Benefits of dabigatran against recurrent VTE maintained 1 year after drug discontinuation
- Dabigatran performed better than warfarin following major bleeds
- Double UCB transplant did not improve survival in children
- Genetic factors associated with heart failure in patients who underwent HCT
- Low hematocrit levels decreased risk of thrombosis among patients with polycythemia vera
- Omission of daunorubicin did not reduce survival among children with ALL
- Oral rivaroxaban superior to standard therapy for VTE
- Twice-daily doses of apixaban reduced risk of VTE